Send to

Choose Destination
See comment in PubMed Commons below
Oncoimmunology. 2013 Mar 1;2(3):e23431.

Naturally circulating dendritic cells to vaccinate cancer patients.

Author information

Department of Tumor Immunology; Nijmegen Centre for Molecular Life Sciences; Radboud University Nijmegen Medical Centre; Nijmegen, The Netherlands ; Department of Medical Oncology; Radboud University Nijmegen Medical Centre; Nijmegen, The Netherlands.


Dendritic cell-based immunotherapy is a promising strategy against cancer that appears to be feasible, safe and to induce potent tumor-specific immune responses. The use of naturally circulating dendritic cells (DCs), rather than cultured monocyte-derived DCs, might constitute the next logical step to translate anticancer immune responses into long-lasting clinical benefits.


cancer immunotherapy; dendritic-cell targeting; dendritic-cell vaccination; myeloid dendritic cells; plasmacytoid dendritic cells

PubMed Commons home

PubMed Commons


    Supplemental Content

    Full text links

    Icon for Taylor & Francis Icon for PubMed Central
    Loading ...
    Support Center